The Pivotal Scientific Portfolio

Partnering for Growth: A New Chapter in Business Collaboration

Published: December 18, 2020

LifeSpan BioSciences, Inc. announces the acquisition of Everest Biotech

Release Date: July 31st, 2019

Seattle, Washington State, USAโ€“ June 2019 โ€“ LifeSpan BioSciences (LSBio), a leading provider of antibodies and life science research reagents is pleased to announce its acquisition of Everest Biotech. Everest Biotech are ISO 9001:2015 certified experts in antigen affinity purified goat polyclonal antibodies.

The acquisition of Everest Biotech further expands the LSBio product offering and strengthens LSBioโ€™s position as one of the fastest growing companies in the research reagent market. LSBio through its partnerships now offers a comprehensive catalogue of reagents that can be coupled with their extensive collection of IHC validated primary antibodies.

โ€œWe are looking forward to adding the Everest Biotech product range to the LSBio portfolio,โ€ said Heather Holemon, CEO of LSBio. โ€œEverest Biotechโ€™s products are of exceptionally high quality and they complement our existing portfolio perfectlyโ€.

Heather Holemon, CEO of LSBio

Everest Biotechโ€™s commitment to quality and continuous improvement has ensured that their catalogue has grown, containing thousands of goat antibodies against a broad range of human, mouse and rat targets of biomedical interest. This will broaden LSBioโ€™s current offering of over 500,000 monoclonal and polyclonal primary antibodies to virtually every protein in the proteome. Through extensive ongoing in-house testing, more than 15,000 of the LSBio antibodies have also been identified as exceptional IHC reagents and given the IHC-plusโ„ข brand.

About LifeSpan BioSciences

LifeSpan BioSciences was founded in 1995 by Doctors Joseph Brown and Glenna Burmer and was established as a molecular pathology company with a focus on protein localisation in diseased human tissue by IHC.

In addition to antibodies and IHC reagents, LSBio offers over 50,000 high-quality immunoassays, including sandwich ELISA (enzyme-linked immunosorbent assay) kits, competitive EIA (Enzyme Immunoassay) kits, as well as cell-based and DNA-binding ELISA kits. LSBio also offers a range of recombinant and native proteins and lysates.

This acquisition of Everest Biotech, is the second by LSBio this year, following the successful integration of the Nordic-MUbio/Exalpha Biologicals Companies in February.

LSBioโ€™s services include custom IHC studies supported by a massive archival human tissue bank, and tissue cross-reactivity screening.

Contact us to find out more.

Stay Informed

Sign up to our newsletter for the latest Industry insights and new technologies.
Subscribe Here